Mufg Securities Americas Inc. Purchases Shares of 8,706 Edwards Lifesciences Co. (NYSE:EW)

Mufg Securities Americas Inc. acquired a new position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 8,706 shares of the medical research company's stock, valued at approximately $645,000.

Other hedge funds also recently modified their holdings of the company. Crowley Wealth Management Inc. bought a new stake in Edwards Lifesciences in the fourth quarter valued at $26,000. Millstone Evans Group LLC acquired a new position in Edwards Lifesciences during the 4th quarter worth approximately $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in Edwards Lifesciences in the fourth quarter worth approximately $30,000. Roble Belko & Company Inc acquired a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $46,000. Finally, Catalyst Capital Advisors LLC bought a new stake in shares of Edwards Lifesciences during the fourth quarter valued at approximately $54,000. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Performance

Shares of EW opened at $77.04 on Thursday. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $95.25. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The stock's fifty day moving average price is $71.73 and its two-hundred day moving average price is $71.62. The firm has a market cap of $45.19 billion, a PE ratio of 11.05, a PEG ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.60 by $0.04. The business had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The company's revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.66 earnings per share. On average, equities research analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 400 shares of the firm's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $69.48, for a total value of $27,792.00. Following the completion of the transaction, the vice president now directly owns 22,588 shares of the company's stock, valued at $1,569,414.24. This trade represents a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $67.96, for a total value of $645,620.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,189,770.56. The trade was a 16.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 71,931 shares of company stock valued at $5,148,028. Company insiders own 1.29% of the company's stock.

Wall Street Analysts Forecast Growth

EW has been the subject of several research reports. Robert W. Baird lifted their price target on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a research report on Thursday, April 24th. Royal Bank of Canada reissued an "outperform" rating and set a $85.00 target price on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Piper Sandler raised their price target on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the company an "overweight" rating in a research report on Tuesday. Barclays lifted their price target on Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. Finally, Wolfe Research downgraded Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research note on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $79.60.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.